The West End economics…
Photo credit: Pamela Raith
There are two questions that underpin the economics of the West End for producers. How many tickets will we sell at what average price, and how much of the upfront capitalisation should and can we lay off to my network of Angels (those who provide the funds in advance in hope of a share of any profits)? If they get that right, it is a very profitable model; if they get it wrong, they can lose all of theirs and their Angels’ investment.
The West End operates on model of a producer hiring a venue for the run by agreeing to a rental fee and paying the contra (the direct costs of opening the theatre for a performance). The financial risk for the production sits firmly with the producer and their financial backers. If the ticket sales don’t take off (hitting over 75% of the capacity these days), the producer will incur losses, fail to recoup pre-opening production costs (the capitalisation) and may ask for a rental waiver from the venue to keep the show on in the hope that word of mouth drives sales. The venue may accept that as the alternative is closure and a period dark with no income.
West End Ticket Prices
The last public SOLT data in May 2025 said that the average cost of tickets had fallen in the last year by 5.3%. The official box office data showed in 2024, the majority of tickets were sold for £56 or less, with over a quarter under £35. Fewer than 4% were priced above £150. The good news is that they reported 17.1million theatregoers attended a West End show in 2024, attracting more customers than Broadway did in same period and well ahead of the pre-pandemic attendances of 15.3m in 2019. The headline prices have changed dramatically as The Stage’s annual survey revealed, with the average top price tickets rising in 2025 to over £173 compared to £119 pre-pandemic, with £300 now occasionally being asked as the recently closed Inter Alia was asking.
The pattern is well established with very popular shows using dynamic pricing or premium prices with extras like a drink and a programme to maximise their income while retaining a low entry level price to promote or attract diverse younger audiences. It is also true that when a show is not selling well, discounts are used to move tickets and fill houses which, in turn, is lowering the ATP. These pricing strategies are logical for producers anxious to recoup their costs and make a return for their financial backers while still trying to ensure a full house for each performance.
Should we be concerned or is this simply a reflection of a nation divided by finance between those who can afford this extravagant discretionary spend and those who can’t? Is it a sign that we are following Broadway down a dangerous path of ever rising staging costs and higher ticket prices which makes producing there so precarious? In our recent visit to New York, we found top shows were half sold at $160 to $300 a ticket the day before a performance but sold out on the day when queues for the Times Square Ticket Booth could be over an hour long to secure the discounts.
To Book or Not to Book, that is the question…
Short runs means a decision needs to be taken as to whether to book or not as there will be less opportunities to catch it later, especially if it opens to strong reviews. Younger audiences appear to be savvy enough to wait and pick up discounted tickets closer to the show date. We have found that if you are lucky, the best prices for best seats are available at the Box Office 10 minutes before the curtain rises, but you risk being disappointed! Indeed, it now appears that buying direct from the venue’s box office even online, secures the best value tickets.
West End Production Risks
Theatre investors have always known it was a hit game, and a long runner that can produce extraordinary returns for the producer and the venue. When ATG acquired the Lyceum in 2000, just one year after The Lion King opened there, its financial analysis couldn’t possibly have predicted that the show would still be running there 25 years later! Equally, when Eleanor Lloyd was trying to launch her revival of Witness for the Prosecution at the site-specific London County Hall in October 2017, many did not believe it would work, but those who backed her have been well rewarded by the combination of Agatha Christie’s name and the atmospheric setting.
As the hit shows (usually musicals) settle in for long runs at the big West End venues, the spaces for other shows has become more limited and when shows close early, there is a rush to fill the slot by venue owners to avoid dark periods, and producers anxious to get their show (and contracted cast) exposure even for a limited window.
What do these short runs in West End mean? Presumably Theatre Tax Relief (TTR) reduces the risk of non-recoupment and enables shorter runs. Nevertheless, if SOLT is correct and the ATP is not rising, but costs are up, these short runs must surely face a higher risk of not recouping costs. They must be depending on an afterlife billed as “direct from West End” to support the investment or have already recouped significant costs on a prior “out of London” tour. It is interesting to see that High Society (playing at the Barbican from 19 May -11 July) will begin a regional tour at the Wycombe Swan on 16 July and then run right through to Eastbourne in November.
The Arts Council’s new touring loan scheme helps a bit by being the last of the cash to be repaid in the event of non-recoupment which adds a little downside protection to Angels.
Our Experience of Investing in Shows
We have invested in the over forty productions, usually taking one unit, the smallest investment you can make in a show. We first invested in 2011 and have now taken small participations in wide range of West End and regional touring shows with different lead producers, and if you add up the total invested, it is around £250,000, although that does recycle recouped cash into the next show. At any one time, we have perhaps £50,000 invested in a selection of shows. Why do it? It is a good question as, unless you are very lucky with an investment in a show like Witness for the Prosecution, it is a very risky business with a high chance of not recouping all of your investment. That can mean that the invite to the press night/after show party and a free programme are very expensive tickets!
We invest for a number of reasons. The insight into the production from the investment prospectus, the updates from the good producers on sales advances and upcoming announcements, the occasional mid-run reception with other investors and the cast, and the data on the overall outcome on the production are fascinating and give a sense of belonging to the production. One producer publicly stated early in our investment that he thanked his philanthropic investors and we suppose there is an element of that, wanting to help bring live theatre to audiences, but we always invest in the expectation of recouping over the production run.
Early in our investment experience, we thought we had a special knack of picking successful shows as the first ten shows we invested in all recouped the £35,000 we had invested, and produced a 40 % profit as well! But then in 2017 came two shows that wrote off 86% of our investment and wiped-out half of those profits. The pattern has continued since but worse since Covid with now fifteen shows failing to recoup, leading to an overall loss over the years of over £25,000 which, in part, reflects those worsening terms for small investors. We suspect that larger investors who put over £100,000 into shows do get better terms as well as a producer credit but we have never had the cash or nerve to do that especially as our worst performing productions have been our biggest investments so far.
The Capitalisation
How does it work? The producer issues a prospectus to his book of potential investors which sets out details of the cast and creative team, and includes high level financial information on the capitalisation (the total amount to be raised before the show opens including contingencies) and the weekly running costs, together with projections of the recoupment and profits from different levels of ticket sales measured as a percent of the financial capacity of the Box Office. The critical factors are the length of the run, the required audience capacity to recoup the capitalisation, the royalty pool (amounts paid to copyright owners and creatives before investor profits are struck) and the spilt of those profits, if any, after recoupment of the capitalisation, between the producers and the investors. Although the generous Conservative government’s Theatre Tax Relief (TTR, now 40% of 80% of eligible pre-production costs) should have reduced the risk of investing, post-Covid we have seen an increase in risk for investors despite the growth in headline ticket prices across the UK.
Capitalisation costs have risen driven in part by inflation, but we suspect also by the front-end loading of costs and creative decisions given that both are offset by the TTR. This clearly then requires higher Box Office to recoup. Weekly running costs have also increased driven partly by the Labour Government’s increases in National Insurance and minimum wages but also by generous settlements with Equity for West End performers and stage management and we suspect increased expectations from star names on the billboards that, after all, sell the tickets.
Play capitalisation in the West End has now risen dramatically whereas pre-Covid, we saw a range of £600,000 to £1,000,000 for a 2 - 4 week run, with weekly costs £150,000 to £200,000 to cover. We now are seeing capitalisation for plays being set at £1.2million to £1.5million, with weekly running costs rising up to £300,000 for a similar length run. Inevitably the required capacity occupancy rises to over 80% at budgeted prices, more if discounting is required to move tickets after less than brilliant reviews.
Musicals are much more expensive with capitalisations of £2,000,000 to £4,000,000 or more, weekly costs of £250,000 to £450,000, and require a bigger venue and long run to recoup. Of course, when the show is a hit and dynamic pricing kicks in, Box Office revenues can rise dramatically from the projections BUT the reverse is also true, when the show does not get the reviews it needs or fails to connect with a larger enough audience, discounting kicks in heavily to fill the venue and the savvy ticket buyers know when to wait and where to buy to get much better value tickets. We have seen shows that have ended the run selling 80% of Box Office tickets but falling very short in income against the projections due to this discounting. We also believe that this is why the headlines of average ticket prices not increasing post-Covid are misleading as the huge rise through dynamic pricing is offset by the heavy discounting in struggling shows.
Investor Share of any Profits
The other huge change is the increase in the royalty pools, mainly to attract those stars to perform or rights holders to grant permission. These royalties will be a combination of a percentage of Net Box Office and a percentage of weekly operating profits (subject to a minimum weekly amount). These have risen and may have a first call on excess income of up to 30%. These pools reduce the surpluses to be shared between producers and investors.
Another trend is the adoption of the US term for the split of profits after royalties. We used to see 60/40 in favour of the small investors but now, increasingly, we see 50/50. As a result, where once £100 of “profit” might have attracted 15% royalty, leaving £85 to be split 60/40 with investors getting £51, now we night see the same £100 with a 25% royalty and 50/50 split, leaving investors with just £37.50, a drop of 26%. When you combine that with a requirement to hit 75% plus of Box Office capacity after TTR to recoup, compared to perhaps 60-70% pre-Covid, the risks can be seen to be much higher while the upside is much lower. This 50/50 split seems to be driven by more US producers coming to UK to invest as the returns are seen as better than the Broadway model which has become highly risky with huge capitalisation costs, higher running costs and a greater risk of bad reviews killing demand for a show. The US producers see the West End as a lower risk try out for a Broadway transfer.
To invest or not invest , the second question…
Should you invest? Probably not unless you can afford to lose your whole investment! We get sent a few prospectuses each month and decide whether to invest or not based on the venue, producer, title (or subject matter), author, cast, dates, and the financial projections and terms. When the production ticks all of these elements, we will definitely still consider investing at the smallest level possible. We currently have small investments in five productions. Three plays that will run in the second half of 2026 and two UK regional tours, one of which we are certain will recoup and return a profit, and one with a title and celebrity casting that we believe should make it a success. Of course, world events or cast illness risks can override all that too.
There are occasionally opportunities to take a portfolio approach to investing in production where a producer raises funds on a long-term basis to fund a range of shows. While this spreads the risk in the investment, it dilutes the connection with each show and the insight that brings and may not offer press night tickets and cast meets as often. Also, since the fund rolls over continually into the next show, the returns are delayed and the capital may be tied up for many years so it is less fun, less likely to repay any cash in the short term but far less risk of a write off! We are in three portfolio investment funds at the moment.
Alternatively, if it is insight and association with a particular production that you seek, the Producers Circle concept or high-level membership might be appealing, though it does not offer any financial recoupment or return. This is more akin to philanthropic support of a favourite venue with some acknowledgement of that support in the programme. Chichester Festival Theatre’s Artists Circle currently costs between £5,000 and £12,000 in return for a “close association with the theatre” or a particular project or area including technical rehearsals, cast meets and discussions, and director reception. The RSC too offers a Production Circle at a cost of £25,000 and promises contributors can witness “the magic unfold at every stage if the creative process”.
If the schemes are offered by charities and structured in the right way, these contributions can be treated as donations attracting gift aid and tax relief. Many venues’ membership schemes offer the lower levels of this association at much lower costs, and it is only when you get invited to the creative and rehearsal process that the cost rises significantly.
To “invest” in theatre production, you need to have a strong passion for live theatre, afford to be able to lose or write off the cash, and pick your venue, production and creatives carefully. There is a lot of trust in the process required as the information flows, benefits and outcomes are always uncertain but if you choose the right productions, even if you don’t get your money back, it can be a very enjoyable experience and you get the satisfaction of playing a small part in bringing the work to new audiences.
Nick Wayne
Nick has been involved as a Trustee/Director in UK Producer and Venue Organisations for twenty-six years, seen over 1350 productions, visited over 160 of the UK Venues, seen overseas productions in USA, Canada, France, Hungary, Austria, Czech Republic, and Australia and invested in over 40 West End Productions. You can read his long form articles on Stage Whispers UK - Nick Wayne